The average market share of Suboxone Film in the US was 6% in 2016, it said, and it accounted for 80% of Indivior’s total revenues last year. Indivior said if pharmacies could substitute Suboxone Film with a generic rival without direct consultation with the patient it could lead to the firm’s treatment losing up to 80% of its market share “within a matter of months”. Indivior said in June it had won a US patent battle against Actavis and Par Pharmaceutical over Suboxone Film. He said: “The one positive from this news is that Indivior’s patents were upheld, and Dr Reddy’s was found to not be infringing on said patents. This could potentially help offset any future generic challenges, as [they] must also show to not be infringing.

Source: The Guardian September 01, 2017 09:20 UTC